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Abstract: Hedgehog (Hh) proteins are prototypical morphogens known to regulate
epithelial/mesenchymal interactions during embryonic development. In addition to its pivotal
role in embryogenesis, the Hh signaling pathway may be recapitulated in post-natal life in a
number of physiological and pathological conditions, including ischemia. This review highlights
the involvement of Hh signaling in ischemic tissue regeneration and angiogenesis, with particular
attention to the heart, the brain, and the skeletal muscle. Updated information on the potential role of
the Hh pathway as a therapeutic target in the ischemic condition is also presented.
Keywords: hedgehog; ischemia; heart; brain; skeletal muscle
1. Introduction
Hedgehog (Hh) signaling was first described in 1980 by Nusslein-Volhard and Wieschaus and was
initially addressed as a key mediator of cellular proliferation, differentiation, and migration during
organogenesis in invertebrates [1]. The general signaling mechanism for the Hh pathway is conserved
from fly to mammal, although more and distinct components have been found in mammalian cells [2].
In the early 1990s, three Hh homologs were discovered in vertebrates: Sonic (Shh), Desert (Dhh), and
Indian hedgehog (Ihh). Among them, Shh is the most widely expressed during development and the
best studied. The initial evidence for the importance of Hh signaling in mammalian development was
provided by observations that mutations in Shh cause holoprosencephaly, a developmental disorder
that affects midline morphogenesis of the face and nervous system [3–5]. Although most studies of Hh
signaling focus on Shh, the other two ligands—Dhh and Ihh—share many of the same downstream
signaling components. The Dhh ligand is more abundant in the reproductive organs of both males and
females, including Sertoli cells of testes and granulosa cells of ovaries [6,7]. Consistent with this, male
mice lacking Dhh are infertile due to the complete absence of mature sperm [6]. Ihh instead plays an
important role in skeletal development, primarily in cortical bone and long bone formation. The most
severe manifestation of Ihh deficiency may be seen in children with acrocapitofemoral dysplasia, who
have short stature and bone defects [8].
It was 2001 when we first reported that the Hh signaling pathway has a role in angiogenesis [9].
Before that seminal publication, there were only sparse observations pointing to the possible
involvement of Hh in vascularizing certain embryonic tissues. For instance, it was known that
hypervascularization of the neuroectoderm occurs upon transgenic overexpression of Shh in the
dorsal neural tube [10], or that Shh-deficient zebrafish has disorganization of endothelial precursors
and an inability to form the dorsal aorta or axial vein [11], or that Shh-deficient mice lack proper
vascularization of the developing lung [12]. Nowadays, there is substantial evidence that the Hh
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signaling pathway is an important player in the regulation of angiogenesis in a number of physiological
and pathological conditions in post-natal life, with multiple implications in the field of cardiovascular
medicine, neurology, and oncology. This review presents an updated summary of our understanding
and the many controversial issues on the role played by the Hh signaling pathway in ischemic tissues,
with a specific focus on heart, brain, and skeletal muscle, which are the tissues with the most robust
literature in this field.
2. Skeletal Muscle
2.1. Activation of the Hh Pathway in the Ischemic Muscle
It is well established that ischemia induces strong upregulation of many components of the Hh
pathway, including the Shh ligand, the Ptch receptor, and the transcription factors Gli1, Gli2, and Gli3,
in the skeletal muscle [13–17]. Nonetheless, the biological mechanisms underlying this phenomenon are
still not completely understood. Experimental data have shown that hypoxia per se—independently of
ischemia—is able to induce a rapid systemic Hh response in various organs of adult mice, with the Hh
response being preceded by the accumulation of the master transcriptional regulator of hypoxia HIF-1α
(Hypoxia-Inducible Factor-1α) [18]. Pharmacological inhibition, knockdown, or genetic ablation of
HIF-1α abolishes Hh pathway activation in hypoxic tissues [18]. HIF-1α inhibition is also sufficient
to block Hh signaling in cancer cells [19]. Based on this, it is plausible that the activation of the Hh
pathway observed in response to ischemia in the skeletal muscle may occur through HIF-1α. However,
a precise role for HIF-1α, specifically in this setting, has not yet been established.
2.2. Effects of Endogenous Hh in the Ischemic Skeletal Muscle
Once the Hh pathway is upregulated, it exerts important regulatory effects on angiogenesis
in the ischemic muscle. There is strong evidence that such regulatory effects mainly occur in an
indirect manner, with the production of angiogenic growth factors by Shh-responding cells, i.e.,
interstitial fibroblasts/mesenchymal cells. This has been demonstrated in vivo in a murine model of
hindlimb ischemia, in which fibronectin-positive interstitial mesenchymal cells within the ischemic
area produce vascular endothelial growth factor (VEGF) through an Hh-dependent mechanism [13].
The fact that the Hh pathway is an indirect stimulator of angiogenesis was originally discovered
using a murine corneal model of angiogenesis, in which pellets containing Shh were implanted in
the cornea of mice carrying the lacZ reporter gene under the control of the Ptch gene promoter [9].
The result was the upregulation of the lacZ reporter gene in corneal interstitial mesenchymal cells,
which indicated that these cellular elements were the Shh-responding cells in this in vivo assay.
It was also demonstrated that these Shh-responding cells were immunopositive for VEGF, which
indicated that they were producing angiogenic growth factors in response to Shh stimulation [9].
These in vivo data were supported by a series of in vitro experiments, which demonstrated that
Shh has the ability to upregulate the expression of angiogenic cytokines, including all three VEGF-1
isoforms and angiopoietins-1 and -2, in fibroblasts [9]. On the other hand, Shh has no direct effect
on endothelial cell migration or proliferation [9]. The capacity of Shh to induce the production of
angiogenic growth factors, including VEGF, hepatocyte growth factor (HGF), platelet-derived growth
factor-BB (PDGF-BB), and insulin-like growth factor (IGF), in interstitial cells and fibroblasts, has been
later confirmed by other authors in various organs and tissues [20–23]. Also, it has been confirmed
that none of the Hh ligands is able to induce Gli-target genes in endothelial cells [24] and that Shh has
limited effects on endothelial cell proliferation and migration [17,24]. There is also the demonstration
that Gli3 deficiency in endothelial cells does not affect the repair of the ischemic skeletal muscle [25].
On the other hand, it has been reported that Hh proteins have the ability to promote endothelial
cell tubulogenesis through a non-canonical Hh pathway that involves Smo, Gi proteins, and Rac1
and results in cytoskeletal rearrangement and formation of actin stress fibers in endothelial cells [24].
Nonetheless, endothelial-specific Smo knockout (eSmoNull) mice have no observable phenotype
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and display unaltered ability to mount an appropriate angiogenic process in response to hindlimb
ischemia [26]. Even Shh-induced corneal angiogenesis is normal in eSmoNull mice [26]. Taken together,
these findings support the concept that the main molecular mechanism through which the endogenous
Hh pathway regulates angiogenesis in the ischemic skeletal muscle is the stimulation of growth factors
production by interstitial mesenchymal cells and fibroblasts. Nonetheless, we have also demonstrated
that Shh plays a role in myogenesis, as its inhibition impairs the activation of the myogenic regulatory
factors Myf-5 and MyoD and reduces the number of myogenic satellite cells in the injured skeletal
muscle site [27,28]. However, these myogenic effects have been demonstrated upon mechanical and
toxic injury of the skeletal muscle, or in experimental models of muscle dystrophy, and it is not known
whether they are relevant also in the setting of ischemia.
Some controversies exist on the identity of the Hh ligand that plays the most important role during
ischemia-induced angiogenesis in the skeletal muscle. We have found that hindlimb ischemia results in
upregulation of Shh expression, without a detectable effect on Ihh and Dhh [13]. We have also recently
found that microparticles (MPs) carrying Shh are increased in humans with peripheral artery disease [29].
However, Caradu and coll. have reported that angiogenesis is not impaired in Shh inducible knockout
mice, opening the possibility that endogenous Shh does not promote ischemia-induced angiogenesis,
but has instead the ability to limit inflammation, macrophage recruitment, and chemokine expression
in myocytes in the ischemic skeletal muscle [30]. This study deserves attention because it used genetic
manipulation tools (Shh inducible deficient mice) to specifically inhibit the activity of endogenous Shh
and test the effects of such inhibition on ischemia-induced angiogenesis. The findings of Caradu and
coll. open the possibility that other Hh ligands, rather than Shh, or in addition to Shh, are important for
ischemia-induced angiogenesis. Consistent with this hypothesis is the notion that Dhh is expressed in
ECs and is important for proper endothelial function [31]. Also, it has been shown that limb perfusion
is significantly impaired in the absence of Dhh [16]. There are data supporting the hypothesis that Ihh
might also have a role in angiogenesis. In particular, Ihh is necessary for the formation of the anterior
aorta and the vascularization of the yolk sac [32,33]. Ihh has also been shown to synchronize skeletal
angiogenesis and perichondrial maturation with cartilage development [34] and to cooperate with
VEGF in tumor angiogenesis [35]. However, a role for Ihh in the ischemic skeletal muscle has not been
demonstrated so far.
2.3. Therapeutic Potentials of Exogenous Activation of the Hh Pathway in Ischemic Skeletal Muscle
Regarding potential therapeutic implications, it has been demonstrated that Shh recombinant
protein, injected intraperitoneally in aged mice, augments blood-flow recovery and limb salvage
following operatively induced hindlimb ischemia [9]. Also, intramuscular treatment with phShh
increases blood flow, capillary density, and arteriole density in old mice in which peripheral circulation
of the hindlimb has been disrupted by removal of the common femoral artery [27]. Shh gene therapy
also enhances vasculogenesis, by increasing the number of circulating bone marrow (BM)-derived
endothelial progenitor cells (EPCs) and improving the contribution of these cells to the process of
neovascularization [15]. Combined therapy with Shh gene transfer and BM-derived EPCs is more
effective than Shh gene therapy alone in an experimental model of peripheral limb ischemia [36]. The
importance of the Hh pathway in the pathophysiology of the EPC compartment has been recently
further strengthened by the demonstration that Gli1 and Ptch expression are reduced in the EPCs of
streptozotocin (STZ)-induced type 1 diabetic mice and that administration of an Shh pathway receptor
agonist (SAG) restores both the number and function of EPCs and increases neovascularization in these
mice in response to ischemia [37]. Finally, there are data supporting a potential therapeutic role also
for Dhh in the ischemic skeletal muscle. In particular, it has been shown that Dhh supports peripheral
nerve survival and maintenance of the pool of nerve-derived proangiogenic factors in the ischemic
muscle and that the rescue of Dhh expression by gene therapy in old mice promotes ischemia-induced
angiogenesis in the murine skeletal muscle [16].
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A summary of the results of the studies conducted on the ischemic skeletal muscle is presented in
Table 1, while a schematic representation of the mechanisms through which the Hh pathway regulates
angiogenesis in the ischemic muscle is presented in Figure 1.
Table 1. Hedgehog in the ischemic skeletal muscle.
Result First Author Journal and Year ofPublication Ref.
Hindlimb ischemia induces Shh and Ptch
upregulation in mice Pola Circulation, 2003 [13]
Hh inhibition with 5E1 antibody decreases
upregulation of VEGF in response to ischemia Pola Circulation, 2003 [13]
Gli3-haploinsufficient (Gli3+/−) mice have reduced
capillary density after induction of
hindlimb ischemia
Renault Circulation Res, 2009 [17]
None of the Hh ligands is able to induce Gli-target
genes in endothelial cells
Shh, Dhh, and Ihh proteins promote endothelial
cell tubulogenesis and cytoskeletal rearrangement
through non-canonical Hh pathways
Chinchilla Cell Cycle, 2010 [24]
Endothelial-specific Smo knockout (eSmonull) mice
do not have reduced angiogenic response
to ischemia
Gupta Lab Invest, 2018 [26]
Inhibition of the endogenous Shh pathway in Shh
inducible knock out (Shh iKO) mice does not
impair angiogenic response to ischemia
Inflammation and macrophage recruitment are
increased in the ischemic skeletal muscle when the
endogenous Shh pathway is inhibited in Shh
iKO mice
Caradu Cardiovasc Res, 2018 [30]
Intraperitoneal injection of Shh recombinant
protein enhances angiogenic response to ischemia
in aged mice
Pola Nature Med, 2001 [9]
Intramuscular treatment with a plasmid encoding
the Shh human gene (phShh) enhances angiogenic
response to ischemia in aged mice
Straface J Cell Mol Med, 2009 [27]
Intramuscular treatment with phShh enhances
skeletal muscle regeneration in aged mice Piccioni
J Gerontol A Biol Sci
Med Sci, 2014 [28]
Intramuscular treatment with phShh increases the
number of bone marrow (BM)-derived endothelial
progenitor cells (EPCs) in response to ischemia
in mice
Palladino Molecular Therapy, 2011 [15]
Combined therapy with phShh and BM-derived
EPCs enhances angiogenesis and myogenesis in
the murine ischemic skeletal muscle
Palladino J Vasc Res, 2012 [36]
Treatment with an Shh receptor agonist (SAG)
restores number and function of EPCs in diabetic
mice and increases neovascularization in response
to ischemia
Qin Mol Cell Endocrinol,2016 [37]
Dhh gene therapy enhances angiogenesis in the
ischemic muscle of aged mice through promotion
of peripheral nerve survival
Renault Circulation Res, 2013 [16]
Treatment with a Dhh-signaling agonist (SAG)
improves endothelial function in diabetic mice
without promoting angiogenesis
Caradu Circulation Res, 2018 [31]
Microparticles carrying Shh are increased in
humans with peripheral artery disease Giarretta Int J Mol Sci, 2018 [29]
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Figure 1. Hh in the ischemic skeletal muscle. The upregulation of the Hedgehog (Hh) pathway 
observed in the ischemic skeletal muscle occurs through unknown mechanisms, perhaps mediated 
by the Hypoxia Inducible Factor-1α (HIF-1α). Sonic hedgehog (Shh) protein acts on fibroblasts, 
which respond by producing angiogenic growth factors (including VEGF, HGF, PDGF-BB, IGF), 
which stimulate proliferation, migration, and survival of endothelial cells (ECs). Shh-responding 
fibroblasts also produce stromal cell-derived factor 1α (SDF1α), which is responsible for the 
recruitment of bone marrow-derived endothelial progenitor cells (BM-EPCs) into the ischemic site. 
Angiogenic growth factors are also produced by peripheral nerves in the ischemic muscle, upon 
Dhh modulation. There is also evidence that Shh limits the inflammatory response to ischemia in the 
skeletal muscle. Finally, there is in vitro evidence that ECs may respond to Hh proteins in a direct 
manner. Such direct stimulation induces EC morphological changes and supports EC tubulogenesis. 
Dashed lines and italic text represent in vitro data. 
3. Heart 
3.1. Activation of the Hh Pathway in the Ischemic Heart  
Ischemia results in the upregulation of Hh signaling in the heart, with strong overexpression of 
Shh and Ptch in the adult mouse during myocardial ischemia [38–40]. Although it is likely that, 
similar to what happens in the skeletal muscle, the main driver of Hh upregulation in the ischemic 
heart is hypoxia; the literature is particularly poor on this topic, with a study by Bijlsma and coll. 
that demonstrated that hypoxia stimulates an accumulation of HIF-1α, followed by a slower 
increase in mature Shh proteins in cultured cardiomyoblast cells [18]. Hwang and coll., as well, 
have evaluated the role of HIF-1α in a cardiomyoblast cell culture assay under hypoxia, finding that 
the inhibition of HIF-1α—by means of the HIF-1α inhibitor 2-methoxyestradiol (2ME2)—results in 
inhibition of the Hh pathway [41]. On the other hand, the same study has also shown that the 
inhibition of the Hh pathway—by means of cyclopamine—leads to inhibition of HIF-1α in 
cardiomyoblasts cultured in hypoxic conditions, suggesting the existence of a reciprocal cross-talk 
between the two pathways [41]. In vivo studies, ideally with knockdown or genetic ablation of HIF-
1α in cardiomyocytes, are needed to elucidate the role of HIF-1α in ischemia-induced upregulation 
of the Hh pathway in the heart.  
3.2. Effects of Endogenous Hh in the Ischemic Heart  
There is evidence that the endogenous Hh pathway has a homeostatic role in the ischemic 
myocardium. In particular, there is a seminal paper by Levine and coll. that demonstrates that 
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3. Heart
3.1. Activation of the Hh Pathway in the Ischemic Heart
Ischemia results in the upregulation of Hh signaling in the heart, with strong overexpression
of Shh and Ptch in the adult mouse during myocardial ischemia [38–40]. Although it is likely that,
similar to what happens in the skeletal muscle, the main driver of Hh upregulation in the ischemic
heart is hypoxia; the literature is particularly poor on this topic, with a study by Bijlsma and coll. that
demonstrated that hypoxia stimulates an accumulation of HIF-1α, followed by a slower increase in
mature Shh proteins in cultured cardiomyoblast cells [18]. Hwang and coll., as well, have evaluated
the role of HIF-1α in a cardiomyoblast cell culture assay under hypoxia, finding that the inhibition of
HIF-1α—by means of the HIF-1α inhibitor 2-methoxyestradiol (2ME2)—results in inhibition of the
Hh pathway [41]. On the other hand, the same study has also shown that the inhibition of the Hh
pathway—by means of cyclopamine—leads to inhibition of HIF-1α in cardiomyoblasts cultured in
hypoxic conditions, suggesting the existence of a reciprocal cross-talk between the two pathways [41].
In vivo studies, ideally with knockdown or genetic ablation of HIF-1α in cardiomyocytes, are needed
to elucidate the role of HIF-1α in ischemia-induced upregulation of the Hh pathway in the heart.
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3.2. Effects of Endogenous Hh in the Ischemic Heart
There is evidence that the endogenous Hh pathway has a homeostatic role in the ischemic
myocardium. In particular, there is a seminal paper by Levine and coll. that demonstrates that
myocardial Hh signaling is required for proper cardiac anatomy and function even in the absence
of ischemia, as it is responsible for the integrity and maintenance of coronary vessels [42]. Xiao and
coll. have reported that, in streptozotocin-induced type 1 diabetic mice, myocardial expression of
Shh, Ptch, and Gli1 is significantly decreased, and this is accompanied by cardiac dysfunction [40].
Controversially, Bijlsma and coll. presented data indicating a deleterious effect of endogenous Shh in
myocardial ischemia. According to this study, the inhibition of Hh signaling through cyclopamine after
the induction of myocardial ischemia in mice would lead to a worse recovery of the left ventricular
function, an increase in the number of apoptotic cells, and, counterintuitively, a reduction in left
ventricular fibrosis. An immunohistochemical study of the cardiac tissue treated with cyclopamine
brought the authors to affirm that endogenous Shh does not induce vascularization after ischemia.
These findings are in conflict with most studies published in the literature. For instance, Levine
and coll. have shown that the inhibition of the Hh pathway through anti-Shh antibodies leads to
a reduction in border zone coronary vessel density and an associated increase in infarct area [42].
Even more convincing evidence was published by Renault and coll., who demonstrated that Gli3
haploinsufficient mice have reduced capillary density and left ventricular ejection fraction after
myocardial infarction [14]. Hh-mediated effects in the ischemic heart probably occur through a double
mechanism, which includes both enhancement of angiogenesis and direct effects on cardiomyocytes.
Indeed, there are convincing data showing that stimulation of angiogenesis takes place in the heart
mainly using the same mechanisms that we have described in the skeletal muscle, i.e., production of
VEGF and/or other angiogenic growth factors by Hh-responding cells [21,38,43] and no direct effects
on ECs by the endogenous Hh signaling [26]. In contrast, it is accepted that Hh is able to exert direct
effects on cardiomyocytes. Indeed, a microarray analysis has identified almost 40 genes specifically
regulated by Shh in cardiomyocyets, including some in the protein-kinase A (PKA) and purinergic
signaling pathways [44].
3.3. Therapeutic Potentials of Exogenous Activation of the Hh Pathway in the Ischemic Heart
Several experimental studies have tested the possibility of enhancing angiogenesis and
improving heart function after myocardial ischemia by acting on the Hh pathway. Our group
has used intramyocardial gene transfer of naked DNA encoding human Shh (phShh) to enhance
neovascularization, reduce fibrosis, and preserve left ventricular function in rabbit and pig models
of acute and chronic myocardial ischemia [38]. Ahmed and coll. have overexpressed Shh in rat
mesenchymal stem cells (MSCs) [45]. The consequence has been increased expression of angiogenic
and pro-survival growth factors in transfected cells, along with improved ability to migrate and form
tubes in vitro. When injected in the ischemic myocardium, Shh-overexpressing MSCs lead to an
increased density of functionally competent blood vessels and preserved function of the left ventricle.
Guo and coll. have overexpressed Shh in cardiac microvascular endothelial cells (CMECs) isolated
from rat heart tissues [46]. This has resulted in increased CMEC viability and decreased apoptosis,
along with increased production of angiogenic factors, including VEGF, fibroblast growth factor (FGF),
and angiopoietins. In a rat model of ischemia-reperfusion, stimulation of an Shh pathway prior
to reperfusion has reduced both infarct size and subsequent arrhythmias by preventing ventricular
repolarization abnormalities [47]. This is an interesting cardio-protective effect of Shh, which seems to
depend on a direct action on cardiomyocytes. Shh has also been reported to promote the angiogenic
capacity of BM-EPCs in the heart [38]. Finally, it has been recently reported that engineered MPs
carrying Shh (MP-Shh+) may be used to increase the vasculogenic abilities of EPCs and their capacity
to produce NO [48].
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The results of the studies conducted on the ischemic heart are summarized in Table 2, while a
schematic representation of the mechanisms through which the Hh pathway regulates angiogenesis in
the ischemic heart is presented in Figure 2.
Table 2. Hedgehog in the ischemic heart.
Result First Author Journal and Year ofPublication Ref.
Ischemia induces upregulation of Shh protein
in the adult mouse heart
Kusano
Bijlsma
Xiao
Nature Med, 2005
Exp Biol Med, 2008
Cardiovasc Res, 2012
[38]
[39]
[40]
HIF-1α is responsible for Hh activation in
hypoxic cardiomyoblasts
Hwang
Bijlsma
Mol Cell Biochem, 2008
J C Mol Med, 2009
[41]
[18]
Endogenous Hh expression does not induce
vascularization, but rather increases apoptosis
and reduces fibrosis in murine ischemic
myocardium
Bijlsma Exp Biol Med, 2008 [39]
Hh signaling is required for the maintenance of
the adult coronary vasculature
Endogenous Hh signaling reduces infarct area
and increases border zone coronary vessel
density after myocardial infarction in mice
Lavine J Clin Invest, 2008 [42]
Gli3-haploinsufficient (Gli3+/-) mice have
reduced capillary density and left ventricular
ejection fraction after myocardial infarction
Renault Circulation Res, 2009 [17]
Upregulation of Shh, Ptch, and Gli1 is impaired
in the ischemic myocardium of diabetic mice Xiao Cardiovasc Res, 2012 [40]
Canonical Shh signaling regulates gene
transcription in cardiomyocytes Carbe
Am J Physiol Heart Circ
Physiol, 2014 [44]
Treatment with an Shh pathway agonist (SAG)
enhances capillary density, reduces infarct size,
and improves cardiac function in diabetic mice
with myocardial infarction
Xiao Cardiovasc Res, 2012 [40]
Intramyocardial gene transfer of phShh induces
production of angiogenic growth factors,
enhances neovascularization, reduces fibrosis,
and preserves left ventricular function in rabbit
and pig models of acute and chronic
myocardial ischemia
Kusano Nature Med, 2005 [38]
Injection in the rat ischemic myocardium of
Shh-overexpressing mesenchymal stem cells
(MSCs) increases blood vessel density and
preserves function of the left ventricle
Ahmed PLoS One, 2010 [45]
Intramyocardial gene transfer of phShh
increases the number of bone marrow
BM-EPCs and their differentiation into
endothelial cells in the myocardium
Kusano Nature Med, 2005 [38]
In a rat model of ischemia-reperfusion,
stimulation of Shh pathway (by a recombinant
peptide or microparticles harboring Shh)
reduces infarct size and arrhythmias
Paulis Sci Rep, 2015 [47]
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demonstrated only in vitro. There is also evidence of a reciprocal activation of HIF-1α by Shh. Hh-
dependent angiogenesis in the ischemic heart occurs indirectly, as it is mediated by the production 
of angiogenic growth factors by myocardial fibroblasts in response to Hh stimulation. Hh-
responding fibroblasts also produce SDF1α, which is responsible for the recruitment of BM-EPCs in 
the ischemic area. There are in vitro data showing that Shh has the ability to regulate the 
transcriptional response of cardiomyocytes, with increased expression of genes involved in cell 
survival. Dashed lines and italic text represent in vitro data. 
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4.1. Activation of the Hh Pathway in the Ischemic Brain 
A number of data support the concept that Hh signaling is an important regulator of 
neurogenesis and angiogenesis in the adult brain. For instance, it is known that Shh is required for 
the maintenance of neural progenitor cells (NPCs) in the adult hippocampus and regulates the 
proliferation of NPCs after ischemia/hypoxia [49]. Middle cerebral artery occlusion is associated 
with increased mRNA encoding both Shh and its transcription factor Gli1, already a few hours after 
induction of brain ischemia [49]. Regarding the molecular mechanisms underlying Hh activation in 
the ischemic brain, neuroinflammation is a documented trigger [50–52]. Shh transcription is 
induced in astrocytes upon exposure of these cells to inflammatory cytokines and Gli1 is 
upregulated in the inflammatory peri-ischemic area in the early stage of stroke [51]. Less 
documented is the role of hypoxia, although it is known that NPCs and neurons increase Shh 
mRNA levels under hypoxic conditions and that Shh is secreted by activated astrocytes when these 
cells are incubated under oxygen-glucose deprivation (OGD) conditions [53]. Not only OGD but 
oxidative stress has also been shown to have the ability to activate the Shh pathway in cultured 
cortical neurons [54]. 
4.2. Effects of Endogenous Hh in the Ischemic Brain 
The importance of endogenous Shh upregulation in the ischemic brain is demonstrated by the 
fact that, upon induction of experimental cerebral ischemia, inhibition of the Shh pathway results in 
increased infarct volume, brain water content, and behavioral deficits [55]. The endogenous Hh 
pathway appears to be important also for the beneficial effects induced by bone marrow stromal 
cells (MSCs) on neurologic recovery after middle cerebral artery occlusion in mice [56]. Indeed, 
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4. Brain
4.1. Activation of the Hh Pathway in the Ischemic Brain
A number of data support the concept that Hh signaling is an important regulator of neurogenesis
and angiogenesis in the adult brain. For instance, it is known that Shh is required for the maintenance
of neural progenitor cells (NPCs) in the adult hippocampus and regulates the proliferation of NPCs
after ischemia/hypoxia [49]. Middle cerebral artery occlusion is associated with increased mRNA
encoding both Shh and its transcription factor Gli1, already a few hours after induction of brain
ischemia [49]. Regarding the molecular mechanisms underlying Hh activation in the ischemic brain,
neuroinflammation is a documented trigger [50–52]. Shh transcription is induced in astrocytes
upon exposure of these cells to inflammatory cytokines and Gli1 is upregulated in the inflammatory
peri-ischemic area in the early stage of stroke [51]. Less documented is the role of hypoxia, although it
is known that NPCs and neurons increase Shh mRNA levels under hypoxic conditions and that Shh
is secreted by activated astrocytes when these cells are incubated under oxygen-glucose deprivation
(OGD) conditions [53]. Not only OGD but oxidative stress has also been shown to have the ability to
activate the Shh pathway in cultured cortical neurons [54].
4.2. Effects of Endogenous Hh in the Ischemic Brain
The importance of endogenous Shh upregulation in the ischemic brain is demonstrated by the
fact that, upon induction of experimental cerebral ischemia, inhibition of the Shh pathway results in
increased infarct volume, brain water content, and behavioral deficits [55]. The endogenous Hh pathway
appears to be important also for the beneficial effects induced by bone marrow stromal cells (MSCs) on
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neurologic recovery after middle cerebral artery occlusion in mice [56]. Indeed, treatment with MSCs
significantly enhances functional recovery after middle cerebral artery occlusion, concurrent with
increases of synaptophysin, synapse density, and myelinated axons along the ischemic boundary zone.
However, these benefits are significantly reduced by blockage of the endogenous Shh pathway [56]. Also,
the beneficial effects displayed by cerebrolysin—a mixture of neurotrophic peptides—in experimental
neurodegenerative diseases and stroke seem to depend on proper activity of the endogenous Hh
pathway [57]. Indeed, cerebrolysin significantly increases neural progenitor cell proliferation and
differentiation into neurons and myelinating oligodendrocytes in rats subjected to embolic stroke.
However, blockage of the Shh signaling pathway with a pharmacological smoothened inhibitor,
cyclopamine, abolishes cerebrolysin-induced in vitro neurogenesis and oligodendrogenesis. Moreover,
profound neurological function improvements were observed in rats treated with cerebrolysin from
week three to week five after stroke onset. However, in vivo inhibition of the Shh pathway with
cyclopamine completely reverses the effects of cerebrolysin on functional recovery. At the mechanistic
level, there are data indicating that activation of endogenous Shh signaling protects neurons from
H2O2-induced apoptosis and increases cell viability [54]. Regarding a possible role of the endogenous
Hh pathway on angiogenesis in the ischemic brain, it has been shown that Shh produced by astrocytes
(when these cells are incubated in under OGD condition) enhances proliferation, migration, and tube
formation of brain microvascular endothelial cells (BMECs) [54].
4.3. Therapeutic Potentials of Exogenous Activation of the Hh Pathway in the Ischemic Brain
In H2O2-treated neurons, exogenous Shh increases the activity of Superoxide dismutase
(SOD) and Glutathione peroxidase (GSH-PX) and decreases the production of Malondialdehyde
(MDA). It also promotes the expression of the anti-apoptotic gene Bcl-2 and inhibits expression of
pro-apoptotic gene Bax. Activation of the Shh signal also leads to an upregulated expression of both
neurotrophic and vascular factors, such as VEGF and brain-derived neurotrophic factor (BDNF) [54,58].
Intracerebroventricular injections of Shh in rats immediately after permanent middle cerebral artery
occlusion reduces infarct volume, leads to improved microvascular density and neuron survival in
the ischemic boundary zone, and improves neurological scores [21]. These beneficial effects occur
along with enhanced VEGF expression [21]. Stimulation of the Shh pathway appears to be beneficial
even if performed not immediately after stroke. Indeed, delayed treatment (one month after stroke)
with an Shh agonist in mice resulted in enhanced functional recovery both in locomotor and cognitive
function [59]. Furthermore, using a genetically inducible neural stem cell-specific reporter mouse line
(nestin-CreERT2-R26R-YFP), which allows the labelling and tracking of neural stem cell proliferation,
survival, and differentiation in ischemic brain, it was shown that post-stroke treatment with an
Shh pathway agonist increases survival of newly born cells derived from both subventricular and
subgranular zones and neurons in the ischemic brain [59]. Huang and coll. have tested whether the
epidural application of the biologically active N-terminal fragment of Shh (Shh-N) may reduce the
extent of ischemic brain injury in rats exposed to a 60 min episode of middle cerebral artery occlusion.
Shh-N was applied topically by placing a fibrin glue over the peri-infarct cortex [60]. They found
that such treatment substantially reduced infarct volumes after seven days of reperfusion. It also
improved behavioral outcomes as assessed by global neurological functions, rotarod test, and grasping
power test. Furthermore, Shh-N attenuated the extents of protein oxidation, lipid peroxidation, and
apoptosis induced by focal ischemia/reperfusion. Immunohistochemical staining revealed that Shh-N
enhanced post-ischemic angiogenesis stimulated the proliferation of nestin-positive neural progenitor
cells (NPCs) and suppressed astrocytosis.
The results of the studies conducted on the ischemic brain are summarized in Table 3, while a
schematic representation of the mechanisms through which the Hh pathway regulates angiogenesis in
the ischemic brain is presented in Figure 3.
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Table 3. Hedgehog in the ischemic brain.
Result First Author Journal and Year ofPublication Ref.
Neuroinflammation triggers Hh activation in
the ischemic brain
Gu
Amankulor
Lalancette-Hebert
Neurochem Res, 2015
J Neurosci, 2009
J Neurosci, 2007
[50]
[51]
[52]
Middle cerebral artery occlusion (MCAO)
induces upregulation of Shh and Gli1 in the
mouse brain
Inhibition of the Hh pathway (with
cyclopamine) suppresses ischemia-induced
proliferation of subgranular neural progenitor
cells (NPCs) in mice
Sims Stroke, 2009 [49]
Inhibition of the Hh pathway (with
cyclopamine) after permanent MCAO increases
infarct volume, brain water content, and
behavioral deficits in rats
Ji Neurosci Lett, 2012 [55]
Inhibition of the Hh pathway (with
cyclopamine) reduces the beneficial effects of
treatment with bone marrow stromal cells
(MSCs) after MCAO
Ding J Cereb Blood FlowMetab, 2013 [56]
Inhibition of the Hh pathway (with
cyclopamine) suppresses the beneficial effects
of cerebrolysin in models of stroke
Zhang Stroke, 2013 [57]
Intracerebroventricular injections of Shh
protein in rats immediately after permanent
MCAO reduces infarct volume, enhances
microvascular density and neuron survival in
the ischemic boundary zone, and improves
neurological scores
Chen Neuroscience, 2017 [21]
Delayed treatment (1 month after stroke) with
an Shh agonist enhances functional recovery in
locomotor and cognitive function in mice
Jin Stroke, 2017 [59]
Post-stroke treatment with an Shh agonist
(SAG) increases surviving newly born cells
derived from the subventricular and
subgranular zone and neurons in the mouse
ischemic brain
Jin Stroke, 2017 [59]
Epidural application of biologically active
N-terminal fragment of Shh enhances
angiogenesis, stimulates proliferation of NPCs,
suppresses astrocytosis, reduces infarct volume,
and improves behavioral outcomes in rats
exposed to a 60-min episode of MCAO
Huang Exp Neurol, 2013 [60]
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5. Other Ischemic Tissues
In addition to the skeletal muscle, heart, and brain, there are some organs, such as liver, lung,
and kidney, in which it has been brought to evidence that the activation of the Hh pathway may be
involved in pathologic angiogenesis, with an effect on fibrogenesis and whole diseased organs fibrotic
degeneration [61].
5.1. Liver
The contribution of Shh signaling to fibrogenesis has been particularly studied in the liver.
Hypoxia-induced pathological angiogenesis is an important phenomenon closely correlated to the
disruption of the hepatic architecture occurring in chronic liver diseases. Feng and coll. elegantly
demonstrated the pro-angiogenic and pro-fibrinogenic role of the canonical Hh pathway in a model of
liver fibrosis in rats. First, they observed high expression of Shh and other hypoxia-associated proteins,
such as VEGF and HIF-1α, in the setting of hepatic fibrosis, consistent with the existence of a hypoxic
micro-environment. Then, they found that treatment with Gli1 antagonist (GANT)-58 results in reduced
the expression of VEGF and Ang-1 and inhibits hepatic stellate cell (HSC)-mediated tubulogenesis.
These actions appear to be mediated by the interaction of Gli1 with the HSP90 gene, involved in
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the stabilization of HIF-1α in an oxygen-independent manner. This study brings to evidence that
Shh-induced angiogenesis in liver hypoxia may be more associated with hepatic fibrosis than to liver
regeneration [62]. Pratap and coll. demonstrated that inhibition of Shh limits ischemia-reperfusion
injury (IRI) in cholestatic rat livers. Preconditioning bile duct ligated rats with cyclopamine before
subjecting them to IRI lead to decreased levels of serum aspartate aminotransferase (AST), alanine
aminotransferase (ALT), and bilirubin levels, reduced liver damage at the histological level, reduced
levels of neutrophil infiltration and expression of proinflammatory cytokines, and inhibited HSC
activation and cholangiocyte proliferation [63]. Conversely, Tuncer and coll. have shown that the
upregulation of Shh through treatment with L-Arginine (L-Arg) in a rat hepatic IRI model reduces
indices of hepatocellular necrosis and leads to a better histopathological score when compared to
untreated ischemic livers. However, it is not possible to ascribe the effects obtained in the study solely
to Shh, due to the concomitant presence of nitric oxide (NO) released by L-Arg [64].
5.2. Lung
Shh signaling in the embryonic respiratory epithelium appears to have a crucial role in the
branching morphogenesis of the lung, and the expression of Ptch by lung mesenchymal cells is vital for
normal lung formation [65]. In the adult lung, the role of Shh has been mainly studied in relation to the
etiology of chronic diseases, such as asthma [66], chronic obstructive pulmonary disease (COPD) [67],
and idiopathic pulmonary fibrosis [68], and lung carcinogenesis [69]. Very few papers, however, are
available on the role of Hh in the hypoxic pulmonary tissue, and none on the lung in the setting of
ischemia. Wang et al. demonstrated in vitro that hypoxia markedly activates the Shh pathway in
human pulmonary arterial smooth muscle cells (HPASMCs) and that the proliferation of these cells in
response to the ischemic injury is mediated at least in part by the Shh pathway [70]. Al Ghouleh et
al. investigated the molecular mechanisms responsible for aberrant vascular remodeling occurring
in pulmonary arterial hypertension (PAH) patients, demonstrating an up-regulation of nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase 1 (Nox1), an increase in reactive oxygen species
(ROS) production and expression of bone morphogenetic protein (BMP) antagonist Gremlin1 (Grem1)
in resistance vessels from PAH patients compared with non-PAH patients [71]. In human pulmonary
arterial endothelial cells (HPAECs), hypoxia induced Nox1 subunit expression, assembly, and oxidase
activity leading to an elevation in Sonic hedgehog and Grem1 expression. The authors stated that these
data support a Nox1-Shh-Grem1 signaling axis in pulmonary vascular endothelium, likely contributing
to the pathophysiological endothelial proliferation underlying PAH [71].
5.3. Kidney
Few studies analyzed the effect of Shh on the ischemic kidney. Some attention has been paid
to the pro- or anti-fibrotic activity of Shh in renal IRI. Ozturk et al. studied the expression of Shh in
murine models of IRI after treatment with L-Arg, a precursor of NO [72]. They showed that treatment
with L-Arg produced a significant overexpression of Shh in tubular epithelial cells, compared with
the sham-control and the IR/untreated group, and reduced the renal dysfunction associated with
IRI of the kidney [72]. Guanqun et al. studied the role of Shh-Gli1 signaling in kidney regeneration
after renal IRI [73]. They showed that IRI activates Shh-Gli1 signaling and is furthermore responsible
for the up-regulation of the ATP-binding cassette, subfamily G, member 2 transporter (ABCG2), an
essential element for kidney regeneration after renal IRI [73]. Similarly, Meng et al. first confirmed that
the expression of Shh in ischemic kidneys is significantly higher than in non-ischemic kidneys [74].
Afterwards, based on the evidence that polydatin, a glucoside of resveratrol extracted by the dried roots
of Polygonum Cuspidatum Sieb., exhibits beneficial effects in ischemic organs such as heart, brain, lungs,
and kidneys, demonstrated that blocking the Shh pathway (through cyclopamine or the Shh antibody
5E1) markedly suppressed the positive effects of polydatin both in ischemic kidneys in unilateral renal
IRI mice in vivo and in renal tubular cells under OGD in vitro [74]. Metabolic derangements, such
as hyperglycemia, are known to impair normal wound healing through a hypothesized mechanism
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involving the persistent activation of profibrotic signaling pathways, such as transforming growth
factor (TGF)-β. Indeed, recovery from transient kidney damage is poorer in the presence of underlying
diseases such as diabetes, leading to a higher incidence of transition from acute kidney injury (AKI)
to chronic kidney injury (CKD) in diabetic patients. Despite the recognized role of Shh in leading to
kidney fibrosis following AKI, its relationship with hyperglycemia is unclear. The results of a study
by Dong-Jin et al. suggest that diabetes induces persistent activation of Shh signaling and indicate
that hyperglycemia itself could be responsible for the activation of Shh during CKD progression after
kidney IRI in diabetic mice [75]. Moreover, in vitro experiments on renal tubular cells show that
hyperglycemia augments the effect of Shh on their profibrogenic phenotype change, thus contributing
to the hypothesis that Shh may have a role in the development of CKD in diabetic patients [75].
6. Canonical Versus Non-Canonical Pathways
Canonically, Hh signaling occurs through the binding of Hh proteins to the twelve-transmembrane
domain receptor Ptch. Binding of a Hh ligand to Ptch results in Ptch internalization and abolishment
of its inhibitory activity on the seven-transmembrane protein Smoothened (Smo). Smo is subsequently
phosphorylated at its intracellular C-terminus and undergoes reciprocal translocation to the plasma
membrane of non-motile cilia. Through an unknown mechanism, ciliary Smo inhibits the downstream
proteolytic processing of GLI2 and GLI3, leading to the production of full-length activated Gli proteins
(GliA). GliA enter the nucleus and stimulate transcription of the ubiquitous Hh target genes, GLI1,
PTCH, and HHIP (Hh interacting protein). When the pathway is off, Gli2 and Gli3 proteins are
converted into truncated repressor forms, named GliR (Gli repressors), which inhibit target gene
transcription. When the pathway is on, GliR production is blocked, and Gli2 and Gli3 proteins are
converted into GliA [76]. The balance between GliR and GliA is of great relevance. Indeed, changes
in the GliR/GliA ratio can lead to developmental defects in humans, demonstrating that the precise
level of Gli activity is critical for the sophisticated patterning events regulated by Hh signaling during
development [77]. In addition to this canonical pathway, there are cellular and tissue responses to Hh
ligands that occur through non-canonical pathways, which mainly utilize one of the three following
mechanisms: (i) core components of Hh signaling interact with each other in a non-contiguous or
atypical way; (ii) components of Hh signaling directly interact with constituents of other molecular
pathways; (iii) Hh signaling occurs via activation of Smo in an Gli-independent way, or via activation
of Ptch in an Smo-independent way [24,76,78].
A limitation of the vast majority of the studies listed in this review is that they have not evaluated
which pathway is acting in what situations. One exception is the study published by Renault and
coll. in 2009, in which it is shown that Gli3-deficient mice have reduced capillary density after
induction of hindlimb ischemia [17]. They also have reduced left ventricular ejection fraction after
myocardial infarction [17]. This indicates that Gli is important in myocardial and muscular response to
ischemia. Another exception is a study published by Gupta and coll. in 2018, in which the ablation
of the canonical pathway in ECs does not affect angiogenic response to ischemia [26]. This finding
supports the concept that, in ischemic situations, Hh proteins do not exert a direct effect on ECs, at
least through the canonical pathway. They instead seem to act through non-canonical pathways, as
suggested by the evidence that Hh proteins may stimulate tubulogenesis in ECs by RhoA via Smo and
Gi proteins [24,79,80]. Also, there is evidence that Shh binding to RhoA GTPase via a non-canonical
Smo-dependent pathway leads to the maturation of EPCs to ECs (a crucial step in angiogenesis and
vasculogenesis) [24,25,79,80]. Another study that provides some information on the pathway(s) used
by Hh to exert its effects in the ischemic heart is that published by Carbe and coll. in 2014 [44]. In this
study, neonatal rat ventricular cardiomyocytes infected with an adenovirus encoding GiCT, a peptide
that impairs receptor-Gi protein coupling, showed reduced activation of Hh targets. In vitro data were
confirmed in transgenic mice with cardiomyocyte-inducible GiCT expression [44]. Transgenic GiCT
mice showed a specific reduction of Gli1 expression in the heart under basal conditions and failed to
upregulate the Hh pathway upon ischemia and reperfusion injury [44]. Of note, none of the studies
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dealing with the Hh pathway in the ischemic brain contains relevant information on which pathways
are involved in the various pathophysiological situations. Indeed, they generally use cyclopamine to
inhibit the Hh pathway or SAG (a Sonic hedgehog agonist) to stimulate the pathway. However, these
methodologies do not help to distinguish between pathways in a rigorous manner.
7. Concluding Remarks
Once believed to be important only during embryonic development, the Hh signaling pathway is
now recognized as a crucial player in many physiological and pathological conditions in post-natal life.
Its role during ischemia-induced angiogenesis and tissue repair has been extensively investigated in
the last two decades and seems to be particularly important in organs such as the heart, the brain, and
the skeletal muscle. Although the precise molecular and cellular mechanisms underlying Hh-mediated
angiogenesis still require full elucidation, there is substantial evidence supporting the concept that the
endogenous Hh signaling pathway has the ability to orchestrate multiple aspects of the angiogenic
response to ischemia, mainly through the production of angiogenic growth factors from interstitial cells
and fibroblasts and the regulation of EPC activity. Nevertheless, there is evidence that many activities
of Hh proteins in the ischemic heart and brain occur through direct stimulation of cardiomyocytes
and neural cells. Based on the concept that the endogenous Hh pathway is important for efficient
angiogenic response to ischemia, several studies have focused on the use of agonists of the Hh pathway
to stimulate therapeutic angiogenesis. Successful results have been achieved in experimental models of
myocardial infarction, ischemic stroke, and peripheral limb ischemia. However, at the moment, there is
a complete lack of data on human subjects, and doubts remain on the actual possibility of manipulating
the Hh pathway in a safe manner in humans. In this context, it is worth pointing out that Shh has been
implicated in the pathogenesis of several types of cancer and that anti-Hh strategies are currently used,
or are under investigation, for the treatment of many neoplastic diseases, including basal cell carcinoma,
acute promyelocytic leukemia, medulloblastoma, small cell lung cancer, pancreatic cancer, intracranial
meningioma, recurrent glioblastoma, prostate cancer, renal cell carcinoma, and colon cancer. Based on
this, it is unseemly that none of the experimental studies performed so far made an effort to evaluate
whether stimulation of angiogenesis by Shh agonists in the ischemic heart, brain, and skeletal muscle
is safe or may have dismal consequences. Studies testing the safety of exogenous administration of Hh
agonists are therefore mandatory in order to understand whether the large amount of experimental
data produced so far has translational significance and potential clinical implications.
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